AMGEN INC (AMGN)
@AMGN.asset
$281.22
At close:
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
Figures
- Sector Healthcare
- Industry Biotechnology
- Index Nasdaq-100, S&P 500
- Market Cap $151.07 B
- Last Earnings Report Feb 14, 2025
- Price Reaction to Earnings Report -5.73%
- Enterprise Value $199.20 B
- Dividend Yield 0.03%
- P/E ratio 36.92
- Price/Sales ratio 4.52
- EV/Sales ratio 5.96
- Price/Book Value 25.70
- Revenue $33.42 B
- EBIT $7.76 B
- Net Income $4.09 B
- Gross Profit $20.57 B
- Free Cash Flow $10.39 B
- EBIT Margin 23.23%
- Gross Margin 61.53%
- FCF Margin 31.10%
- Return on Equity 69.59%
- Equity Ratio 6.40%
- Debt/Equity Ratio 14.63
- 6-month Performance -10.47%
- 12-month Performance 4.12%
- Trend reversal bad
What the community is saying
| Nobody said anything, yet! Speak your mind and be the first to create a new topic. |